SGK

Serum-glucocorticoid regulated kinase; Serum and glucocorticoid-regulated kinase

Serum- and glucocorticoid-inducible kinases (SGKs) form a novel family of serine/threonine kinases that are activated in response to a variety of extracellular stimuli. SGK family contains three isoforms: SGK1, SGK2, and SGK3. The mRNA encoding SGK1, the best-studied member of the SGK family, is rapidly induced in response to a variety of stimuli, including growth factors, steroid and peptide hormones, cytokines, changes in cell volume, and brain injury.

SGKs are related to Akt (also called PKB), a serine/threonine kinase that plays a crucial role in promoting cell survival. The SGK family members share similar structure, substrate specificity and function with AKT and signal downstream of the phosphatidylinositol 3-kinase (PI3K) signalling pathway. They regulate a range of fundamental cellular processes such as cell proliferation and survival, thereby playing an important role in cancer development. In addition, SGKs not only regulate cell proliferation and survival, but also play important roles in cancer development via an AKT-independent signalling pathway. The importance of SGKs in cancer development and the scarcity of potent and selective SGK inhibitors support the urgent need for discovery and development of small molecules inhibitors targeting SGK for PIK3CA mutant cancers, and especially those that are resistant to AKT inhibition.

SGK Inhibitors

CKI-7

Cat. No.: HY-W011109

CKI-7 is a potent and ATP-competitive **casein kinase 1 (CK1)** inhibitor with an IC_{50} of 6 μM and a K_i of 8.5 μM. CKI-7 is a selective **Cdc7 kinase** inhibitor. CKI-7 also inhibits **SGK**, **ribosomal S6 kinase-1 (S6K1)** and **mitogen- and stress-activated protein kinase-1 (MSK1)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CKI-7 free base

Cat. No.: HY-133028

CKI-7 free base is a potent and ATP-competitive **casein kinase 1 (CK1)** inhibitor with an IC_{50} of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective **Cdc7 kinase** inhibitor.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EMD638683

Cat. No.: HY-15193

EMD638683 is a highly selective **SGK1** inhibitor, with an IC_{50} value of 3 μM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EMD638683 R-Form

Cat. No.: HY-15193A

EMD638683 R-Form is the R-form of EMD638683. EMD638683 is a highly selective **SGK1** inhibitor with IC_{50} of 3 μM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EMD638683 S-Form

Cat. No.: HY-15193B

EMD638683 S-Form is the S-form of EMD638683. EMD638683 is a highly selective **SGK1** inhibitor with IC_{50} of 3 μM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK 650394

Cat. No.: HY-15192

GSK 650394 is a novel **SGK** inhibitor with IC_{50} of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits **influenza virus** replication.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Hu7691

Cat. No.: HY-132302

Hu7691 is an orally active, selective **Akt** inhibitor with IC_{50}s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hu7691 free base

Cat. No.: HY-132302A

Hu7691 free base is an orally active, selective **Akt** inhibitor with IC_{50}s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-4950834

Cat. No.: HY-122011

PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive **rho kinase** inhibitor with IC_{50} values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC SGK3 degrader-1

(SGK3-PROTAC1)

Cat. No.: HY-125878

PROTAC SGK3 degrader-1 (SGK3-PROTAC1), is a potent **SKG3** degrader based on **von Hippel-Lindau** ligand.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SGK1-IN-1

Cat. No.: HY-18607

SGK1-IN-1 is a highly active and selective inhibitor of **SGK-1**, with an IC_{50} of 1 nM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGK1-IN-2

Cat. No.: HY-135893

SGK1-IN-2 (14h) is a selective **SGK1 (serum and glucocorticoid regulated kinase 1)** inhibitor, with an IC_{50} of 5 nM at 10 μM ATP concentration.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGK1-IN-3

Cat. No.: HY-142686

SGK1-IN-3 (compound 3a) is a potent and orally active inhibitor of **SGK1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGK1-IN-4

Cat. No.: HY-142687

SGK1-IN-4 (compound 17a) is a highly selective, orally active **SGK1** inhibitor. SGK1-IN-4 can be used for osteoarthritis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg